The European Union Medical Devices Regulation (EU MDR 2017/745) has fundamentally changed the requirements to maintain access to the European market for medical device manufacturers. The regulation, which came into force in May 2021, has put more stress on clinical evidence, risk management, post-market surveillance, transparency, and the entire lifecycle of a device.

So, for manufacturers, MDR compliance is not just a CE mark issue. It is an ongoing process starting from classification and conformity assessment, and following through clinical evaluation, market access, post-market surveillance, and vigilance.

The regulatory environment is changing as well. In 2026, the European Commission confirmed that four EUDAMED modules are mandatory from 28 May 2026: Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance. Given the above developments, medical device companies can utilise the following checklist to identify key areas that should not be missed.

Confirm the Correct Device Classification

One of the first and most important steps in an MDR compliance strategy is classification.

This classification under the MDR is based on several elements such as the intended purpose of the device, the duration of use, the invasiveness, the active or non-active nature, and the risks. The classification determines the path to conformity assessment and thus the level of regulatory scrutiny required. This is particularly difficult when a product borders on the boundary of classifications or when its intended use has shifted.

The European Commissions Medical Device Coordination Group (MDCG) keeps updating the guidance in this area. In April 2026, the Commission issued a revised MDCG 2021-24 on the classification of medical devices.

Compliance checklist:

• Confirm the intended use and the indications for use
• Apply the relevant MDR classification rules.
• Document the basis for the classification decision.
• Re-evaluate classification if the intended purpose, technology, or design changes.
• Focus on borderline and higher risk devices.
  
  

Classification decisions should therefore be considered as a documented regulatory assessment, rather than a mere administrative exercise.

Build Sufficient Clinical Evidence

Another area where the MDR has raised the bar significantly is clinical evaluation.

The MDR requires manufacturers to supply suitable clinical evidence for demonstration of safety and performance. More importantly, clinical evaluation is not a one-time event. Evidence needs to be reviewed and updated throughout the life cycle of the device.

This is supported by findings in BSIs white paper Clinical Evaluation Under EU MDR. The white paper states that regulatory evolution has increased the importance of planning clinical evaluations, defining the appropriate scope, collecting and appraising clinical data, conducting benefit-risk assessments, and maintaining the evaluation using post-market information.

A quantitative study of manufacturers experiences with the MDR found that the quantity of data needed to provide adequate clinical evidence was the most commonly reported challenge across device risk classes. This underscores why manufacturers should not wait until the conformity assessment stage to discover gaps in evidence.

Compliance checklist:

• Develop a written Clinical Evaluation Plan.
• Determine appropriate sources of clinical data.
• Assess the quality and relevance of the available evidence.
• Identify gaps in evidence early.
• Keep the Clinical Evaluation Report.
• Connect clinical evaluation to PMCF and PMS activities.
• Re-evaluate the benefit-risk profile throughout the device lifecycle.
  
  

Also important for companies entering Europe from other markets is not to assume that evidence accepted elsewhere will automatically satisfy EU MDR expectations.

Select and Prepare for the Appropriate Conformity Assessment

For devices requiring Notified Body involvement, conformity assessment can be one of the most resource-intensive parts of the MDR process.

The correct route is very much based on the type and nature of the device. Higher risk devices generally require more extensive assessment. In Emergo, UL looks at the EU MDR conformity assessment options and the need to identify the right CE-marking pathway while addressing the MDRs increased requirements for classification, conformity assessment, and General Safety and Performance Requirements (GSPRs).

Real-world industry data also illustrates the magnitude of the problem. A recent review of notified-body survey data reported that by summer 2023 notified bodies had received about 13,000 MDR applications; the following year that number had more than doubled to over 26,000. The same analysis found that 75% of notified bodies thought submissions were only 50% complete or less, and in 75% of cases, MDR product certification took longer than a year in 2024. These results show why submission quality matters.

Compliance checklist:

• Determine if the involvement of a Notified Body is required.
• Select a Notified Body having the appropriate designation and scope.
• Know the conformity assessment procedure prior to submission.
• Conduct an internal documentation gap analysis.
• Make sure technical documentation is complete and consistent.
• Be ready for possible questions and requests for more information.
  
  

Better preparation can help reduce unnecessary delays in the evaluation process.

Keep Technical Documentation Consistent and Current

Technical documentation is the foundation of an MDR submission.

It shall provide sufficient evidence that the device complies with the relevant General Safety and Performance Requirements. This covers topics such as device description, design and manufacturing information, risk management, clinical evaluation, verification and validation, labelling and post-market surveillance.

One common problem is inconsistency among documents. For example, the intended purpose as described in the technical file should be consistent with the clinical evaluation, risk management documentation, labelling, and post-market surveillance strategy. The MDR should therefore be seen as an integrated system rather than as a collection of separate documents.

Compliance checklist:

• Alignment of purpose across documentation
• Link risk management to clinical assessment.
• Confirm that the verification and validation evidence support the device claims.
• Retain existing labelling and instructions for use.
• Establish effective document control procedures.
• Record and assess significant changes in a suitable manner.

The aim is not to produce more documentation, but to produce a coherent trail of evidence.

Prepare for EU Market Access and EUDAMED

Regulatory data and registration are becoming increasingly important for market access under the MDR.

EUDAMED the European database on medical devices is aimed at increasing the transparency and traceability of the medical device lifecycle. Four EUDAMED modules will be mandatory as of 28 May 2026: Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance. For manufacturers, that means regulatory readiness is now data readiness.

For example, the Actor Registration module allows economic operators to register and obtain a unique Single Registration Number (SRN). The Notified Bodies & Certificates module also allows for enhanced visibility into certificates, with details of certificates issued, amended, suspended, reinstated, withdrawn, or refused.

Compliance checklist:

• Identify relevant economic operators.
• Keep UDI and device information accurate and up to date.
• Check certificate details.
• Maintain regulatory data consistent across systems.
• Follow up on EUDAMED implementation updates
• Ensure responsible teams understand new registration duties.

Strengthen Post-Market Surveillance and Vigilance

Compliance doesnt stop when the device hits the market.

The MDR puts great emphasis on post-market surveillance (PMS), vigilance, and continuous evaluation of safety and performance. The European Commission says the MDR is more focused on a lifecycle approach based on clinical data and post-market monitoring.

Post-marketing data can further inform the clinical evaluation. The MDCG guidance notes that the clinical data collected during post-market surveillance and post-market clinical follow-up should be used to update the clinical evaluation and associated documentation.

In practice, manufacturers should monitor complaints, incidents, trends, and performance data and assess if these findings affect the benefit-risk profile of the device.

Compliance checklist:

• Prepare a documented plan of PMS.
• Identify sources of data and indicators to be monitored
• Keep up vigilance procedures.
• Carry out systematic analysis of complaints and incidents.
• Implement PMCF as appropriate.
• Feed post-market findings into clinical evaluation and risk management.
  
  

This creates a constant feedback loop from the market to the regulatory system.

Don't Underestimate Clinical Investigation Requirements

Planning is especially important for devices to be studied in clinical trials.

The European Commission states that clinical investigation is essential to demonstrate the safety and performance of medical devices. In line with Article 77(5) of the MDR, sponsors are required to submit a report of the clinical investigation to the relevant Member States within one year of its completion or within three months in the case of early termination or temporary halt.

This requires that clinical investigations be integrated into the overall regulatory strategy from the beginning. Manufacturers should consider the regulatory objective, the endpoints, the requirements for evidence, the applicable national requirements, and how the resulting data will support the clinical evaluation.

Treat Compliance as a Continuous Process

Perhaps the most important item on an MDR checklist is the understanding that compliance is not a destination.

Regulatory guidance is still evolving, EUDAMED is being phased in gradually, classification guidance is updated, and manufacturers need to constantly re-assess their devices in light of new information.

The European Commissions current library of guidance documents for the MDR has updated documents on subjects including software classification, notified body processes, legacy devices, language requirements, and EUDAMED implementation. This is making regulatory intelligence increasingly important for manufacturers.

Therefore, a successful MDR compliance program should involve regular review of:

• Regulatory guidance.
• Classification of apparatus.
• Clinical evidence.
• Risk Management.
• Technical documentation.
• Requirements of the Notified Body.
• PMS data and vigilance.
• EUDAMED requirements.
• Changes to the device or intended use.
  
  

Conclusion

The EU MDR compliance journey doesnt end when you receive a CE mark. The regulatory pathway is classification-driven. Supported by clinical evidence on safety and performance.